DOWNSTREAM PROCESSING FEATURED ARTICLES
Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline plan to initiate Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.
-
COTI-2 Found To Correct Specific p53 Gene Mutation In Human Ovarian Cancer Cells
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) released important new test results today proving that COTI-2, the company's lead oncology candidate, stops cancer cells from replicating by correcting the effects of specific genetic errors affecting the p53 gene.
-
New Gene Mutations Linked To ALS And Nerve Cell Growth Dysfunction
Researchers have linked newly discovered gene mutations to some cases of the progressive fatal neurological disease amyotrophic lateral sclerosis - ALS, also known as Lou Gehrig's disease.
-
Ablynx's Anti-IL-6R Nanobody, ALX-0061, Shows Excellent 24 Week Safety And Efficacy Results In A Phase II Clinical Trial In Rheumatoid Arthritis
Ablynx (EURONEXT BRUSSELS: ABLX) today announced efficacy and safety data for its anti-IL-6R Nanobody, ALX-0061, at the 24 week final analysis of the Phase II part of a combined Phase I/II study in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
![Bio-rad]( "Selecting The Optimal Resins For The Process Purification Of Native And Recombinant Proteins")
Selecting The Optimal Resins For The Process Purification Of Native And Recombinant ProteinsNative and recombinant proteins are used in a variety of applications ranging from drug discovery to target validation to high-throughput screening. Due to this, large-scale protein production and purification have become major necessities in industrial settings.
-
![FiT_MaxiCaps-_20158]( "Accelerating Biopharmaceutical Development From DNA To Drug")
Accelerating Biopharmaceutical Development From DNA To DrugIn the last decade, single-use solutions for virtually every bioprocess unit have been developed, and considerable investments have been made by the industry into areas that underpin this technology.
-
Avoiding Drug Shortages With Microbial Detection
Over the past year, critical drug shortages used to treat a host of life-threatening illnesses have been making headlines. Microbial contamination has been cited as a major contributor to the shortage, yet the prevailing practices to ensure the safety of drugs have been slow to change. In most cases, quality assurance practices safeguarding the drug making environment continue to rely on periodic air and a culturing method from a prior century. By Aric Meares, President and CEO, BioVigilant
-
![CPC AQ variety (feature)]( "Single-Use Connections Advance Aseptic Processing")
Single-Use Connections Advance Aseptic ProcessingJohn Boehm discusses how single-use connections advance aseptic processing and create increased process flexibility and reliability while reducing costs.
-
White Paper: Economic Analysis Of Single-Use Tangential Flow Filtration For Biopharmaceutical Applications Prior to creating an accurate economic model for TFF, a thorough understanding of the process where the TFF is used is needed. A process model is a valuable tool when properly executed and it must accurately include all critical aspects of the purification process. By Michael LaBreck, Mark Perreault, Novasep
-
Global Biochemical Profiling For Bioprocess Optimization
It is widely understood that the production phase of bioprocessing can have a significant impact on the overall profitability of the biopharmaceutical.
DOWNSTREAM PROCESSING PRODUCTS
Time-to-clinic and time-to-market are two key factors in successful biopharmaceutical development.
DOWNSTREAM PROCESSING MULTIMEDIA
Bioprocess With The Bozenhardts is back, with a fresh episode packed with advice from Herman and Erich on the selection of filling systems for biopharmas. Listen in as the Bozenhardts give us an update on the process, logistics, and administration trends that are informing filling system decisions today, and offer direction on making choices that will prepare you for the fast-advancing therapies of tomorrow.
Bio-Rad now offers two very high capacity ion exchangers: Nuvia S, which can be used for capture and/or intermediate polishing; and Nuvia Q, which can be used for intermediate and/or final polishing.